SLNO SOLENO THERAPEUTICS INC

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

SOLENO THERAPEUTICS INC (SLNO) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 8.01: Other Events
Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• Jennifer Fulk appointed CFO effective ~March 2, 2026; succeeds James Mackaness, who retires by end of March — voluntary departure, no disagreement
• Fulk compensation: $525K base salary, 45% annual target bonus, stock options for 67,660 shares (4-yr vest, 1-yr cliff), 39,200 RSUs (4 equal annual installments)

+3 more insights

Item 8.01 · Other Events

• CFO transition: Mrs. Fulk appointed as incoming CFO, Mr. Mackaness retiring from the role
• Effective date of transition tied to February 26, 2026 press release announcement

+1 more insights

Other SOLENO THERAPEUTICS INC 8-K Filings

8-K Mar 16, 2026

8-K Feb 25, 2026

Get deeper insights on SOLENO THERAPEUTICS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.